Mirabegron 50 MG

DRUG14 trials

Sponsors

Astellas Pharma Europe Ltd., Thomas Jefferson University, Buddhist Tzu Chi General Hospital, Unity Health Toronto, Mansoura University

Conditions

AchalasiaChronic Orthostatic IntoleranceDetrusor OveractivityKidney StonesMales With Benign Prostatic Hyperplasia SymptomsNephrolithiasisNocturiaObesity

Early Phase 1

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

TerminatedNCT03411252

Thomas Jefferson UniversityAchalasia

Start: 2018-02-15End: 2019-12-15Updated: 2021-03-24

Phase 2

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Buddhist Tzu Chi General HospitalOveractive Bladder Syndrome

Start: 2018-08-01End: 2019-07-31Target: 130Updated: 2018-08-24

Mechanisms for Activation of Beige Adipose Tissue in Humans

RecruitingNCT04666636

Philip KernPreDiabetes

Start: 2020-12-07End: 2026-12-01Target: 65Updated: 2026-02-03

Using Mirabegron to Increase BP in Patients With POTS

CompletedNCT06133075

Cedars-Sinai Medical CenterChronic Orthostatic Intolerance, Postural Orthostatic Tachycardia Syndrome, Syncope

Start: 2023-12-22End: 2025-07-25Updated: 2025-08-01

A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)

Not yet recruitingNCT06181591

Seoul National University HospitalOveractive Bladder

Start: 2024-04-01End: 2025-04-15Target: 44Updated: 2024-03-08

Phase 3

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

CompletedNCT01908829

Astellas Pharma Europe Ltd.Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases

Start: 2013-07-10End: 2014-11-25Updated: 2024-10-31

Mirabegron And Ureteral Stent-related Pain (MAP) Trial

Unity Health TorontoNephrolithiasis

Start: 2020-02-03End: 2021-06-30Target: 142Updated: 2020-02-26

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Mansoura UniversityStent Related Symptoms, Ureteral Stent

Start: 2021-12-01End: 2022-07-01Target: 240Updated: 2021-11-23

Phase 4

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)

CompletedNCT04907032

University of Alabama at BirminghamOveractive Bladder

Start: 2021-10-01End: 2023-04-15Updated: 2023-07-20

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

RecruitingNCT05051436

Philip KernObesity, Pre-diabetes

Start: 2021-12-13End: 2026-08-01Target: 96Updated: 2026-02-03

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

RecruitingNCT05604222

Shachi TyagiNocturia, Urgency Urinary Incontinence

Start: 2023-03-05End: 2027-03-31Target: 120Updated: 2025-05-13

THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS

CompletedNCT06124066

Hasanuddin UniversityKidney Stones, Ureteral Stenosis, Ureteral Stone

Start: 2022-07-01End: 2022-10-30Updated: 2023-11-13

Unknown Phase

Impact of Mirabegron on Erectile Function in BPH Patients

Kasr El Aini HospitalMales With Benign Prostatic Hyperplasia Symptoms

Start: 2020-10-01End: 2021-10-01Target: 100Updated: 2020-08-10

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Chang Gung Memorial HospitalDetrusor Overactivity, Overactive Bladder Syndrome

Start: 2021-03-01End: 2022-12-31Target: 400Updated: 2021-01-27

Related Papers

PD36-02 MIRABEGRON ADD-ON TREATMENT TO SOLIFENACIN IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS: A RESPONDER ANALYSIS OF A RANDOMIZED, DOUBLE BLIND, PHASE 3B STUDY

The Journal of Urology2016-03-28

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

European Urology2016-03-08181 citations